Literature DB >> 11055240

Possible role of cytotoxic T cells in acute liver injury in hepatitis C virus cDNA transgenic mice mediated by Cre/loxP system.

T Wakita1, A Katsume, J Kato, C Taya, H Yonekawa, Y Kanegae, I Saito, Y Hayashi, M Koike, M Miyamoto, Y Hiasa, M Kohara.   

Abstract

A line of hepatitis C virus (HCV) transgenic mice was established previously that was mediated by Cre/loxP system using HCV cDNA, including core, E1, E2 and NS2 genes. Intravenous infection of a recombinant adenovirus that expresses Cre DNA recombinase (AxCANCre) induced HCV structural protein expression in the liver of transgenic mice. HCV core protein production and transgene recombination in the mouse liver were serially evaluated after AxCANCre infusion. Core proteins were expressed efficiently and transgene was almost completely recombined in the liver of mice after 3 days and then the levels of both core protein production and transgene recombination decreased continuously for 28 days. However, 30.6% of the transgene recombination remained at 28 days and only 2.7% of core production remained at 28 days after infection. Compared with nontransgenic controls, the serum alanine aminotransferase levels in transgenic mice were significantly higher 10, 14, and 21 days after adenovirus infection. Histological scoring also indicated severe pathological changes in the liver of transgenic mice after adenovirus infection. AxCANCre infusion increased CD8+ lymphocyte infiltration into the liver of transgenic mice compared with that of non-transgenic controls. Furthermore, cytotoxic T lymphocytes (CTLs) isolated from transgenic mice during liver injury were specific for the HCV proteins. These results suggest that HCV structural proteins expressed in the liver of transgenic mice enhanced liver injury. HCV-specific CTLs may be to enhance hepatitis. Thus, the present HCV transgenic mouse model provides a useful model of liver injury due to HCV, and the host immune response may play a pivotal role(s) in the pathogenesis of HCV.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11055240     DOI: 10.1002/1096-9071(200011)62:3<308::aid-jmv2>3.0.co;2-6

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

1.  Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses.

Authors:  Nadia Alatrakchi; Camilla S Graham; Hans J J van der Vliet; Kenneth E Sherman; Mark A Exley; Margaret James Koziel
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

2.  Generation of the regulatory protein rtTA transgenic mice.

Authors:  Kang Xu; Xin-Yan Deng; Ying Yue; Zhong-Min Guo; Bing Huang; Xun Hong; Dong Xiao; Xi-Gu Chen
Journal:  World J Gastroenterol       Date:  2005-05-21       Impact factor: 5.742

Review 3.  Liver immune-pathogenesis and therapy of human liver tropic virus infection in humanized mouse models.

Authors:  Moses T Bility; Feng Li; Liang Cheng; Lishan Su
Journal:  J Gastroenterol Hepatol       Date:  2013-08       Impact factor: 4.029

4.  Parenchymal expression of CD86/B7.2 contributes to hepatitis C virus-related liver injury.

Authors:  Jiaren Sun; Batbayar Tumurbaatar; Junhui Jia; Hong Diao; Francis Bodola; Stanley M Lemon; Wendell Tang; David G Bowen; Geoffrey W McCaughan; Patrick Bertolino; Teh-Sheng Chan
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.

Authors:  Gerald Willimsky; Karin Schmidt; Christoph Loddenkemper; Johanna Gellermann; Thomas Blankenstein
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

Review 6.  New animal models for hepatitis C viral infection and pathogenesis studies.

Authors:  Dina Kremsdorf; Nicolas Brezillon
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

Review 7.  Immune responses during acute and chronic infection with hepatitis C virus.

Authors:  Shigeaki Ishii; Margaret James Koziel
Journal:  Clin Immunol       Date:  2008-06-02       Impact factor: 3.969

8.  Immunization with a recombinant vaccinia virus that encodes nonstructural proteins of the hepatitis C virus suppresses viral protein levels in mouse liver.

Authors:  Satoshi Sekiguchi; Kiminori Kimura; Tomoko Chiyo; Takahiro Ohtsuki; Yoshimi Tobita; Yuko Tokunaga; Fumihiko Yasui; Kyoko Tsukiyama-Kohara; Takaji Wakita; Toshiyuki Tanaka; Masayuki Miyasaka; Kyosuke Mizuno; Yukiko Hayashi; Tsunekazu Hishima; Kouji Matsushima; Michinori Kohara
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

Review 9.  Mouse models for the study of HCV infection and virus-host interactions.

Authors:  Heidi Barth; Eric Robinet; T Jake Liang; Thomas F Baumert
Journal:  J Hepatol       Date:  2008-04-14       Impact factor: 25.083

10.  An inducible transgenic mouse model for immune mediated hepatitis showing clearance of antigen expressing hepatocytes by CD8+ T cells.

Authors:  Marcin Cebula; Aaron Ochel; Upneet Hillebrand; Marina C Pils; Reinhold Schirmbeck; Hansjörg Hauser; Dagmar Wirth
Journal:  PLoS One       Date:  2013-07-15       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.